Harvard study reveals how Epstein-Barr virus triggers multiple sclerosis

Researchers at Harvard have identified the biological pathway through which Epstein-Barr virus—the common pathogen behind infectious mononucleosis—appears to set off the cascade of immune dysfunction that leads to multiple sclerosis. The discovery marks a significant shift in how scientists understand the disease's origins and opens a new therapeutic direction: instead of suppressing the immune system broadly, doctors might one day treat MS by targeting the virus itself with antivirals.

Multiple sclerosis affects millions of people worldwide, progressively damaging the nervous system as the immune system mistakenly attacks the protective coating around nerve fibers. For decades, the disease has been treated with immunosuppressive drugs that dial down immune activity across the board—a blunt instrument that comes with its own risks. But this Harvard work suggests a more precise intervention might be possible. By understanding exactly how EBV infection triggers the specific immune responses that go awry in MS, researchers have identified a potential leverage point: stop the virus, and you may prevent the autoimmune cascade from starting in the first place.

The connection between EBV and MS has long been suspected. Nearly all MS patients carry evidence of past EBV infection, and the virus is nearly ubiquitous in the general population—most people encounter it by adulthood, often asymptomatically or with mild cold-like symptoms. Yet only a fraction of infected people develop MS, which suggested that something about how certain individuals' immune systems respond to EBV might be the critical factor. The Harvard team set out to map that response in detail, examining how the virus activates specific immune cells and what happens when those cells begin attacking the nervous system.

What they found was a specific immunological mechanism: EBV infection appears to activate T cells in a way that primes them to attack myelin, the insulating sheath around nerve fibers that is the primary target in MS. The virus essentially trains the immune system to recognize and destroy the very tissue it should be protecting. This discovery transforms EBV from a mere risk factor into a direct causal agent—not just something that correlates with MS, but something that actively initiates the disease process.

The implications for treatment are substantial. If antivirals can suppress or eliminate EBV infection before it triggers this immune cascade, they might prevent MS from developing altogether in people at high risk. For those already diagnosed, antivirals might slow or halt disease progression by removing the ongoing stimulus that keeps the autoimmune response active. This represents a fundamental departure from current MS therapy, which focuses on managing symptoms and slowing progression through immune suppression rather than addressing the root cause.

The research also suggests a potential preventive strategy: identifying people who carry EBV and are at genetic or immunological risk for MS, then treating them with antivirals before symptoms appear. Such an approach would require careful patient selection and long-term follow-up studies, but the possibility of preventing a serious neurological disease before it takes hold is compelling.

The next phase will be translating these laboratory findings into clinical trials. Researchers will need to test whether antiviral drugs can actually prevent MS in at-risk populations, and whether they can improve outcomes in people already living with the disease. The work also raises questions about timing—whether early intervention in childhood or young adulthood, when EBV infection typically occurs, might be most effective. For the millions managing MS today, and for those who may develop it, this Harvard discovery offers a new direction: not suppressing immunity broadly, but stopping the virus that appears to set the whole destructive process in motion.